Navigation Links
Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results

NEW BRUNSWICK, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the three months ended September 30, 2009.

Net loss for the three month period ended September 30, 2009 was $189,296, or $0.01 per share, compared with a net loss of $1,181,406, or $0.06 per share, for the three month period ended September 30, 2008. This decrease in net loss was primarily the result of an increase in non-cash income related to the change in fair value of a warrant liability, which was partially offset by an increase in operating expenses and non-cash expenses associated with the outstanding convertible notes and a decrease in revenue and interest income.

Quarterly and Recent Highlights

  • Senesco presented pre-clinical stability and biological activity data on multiple myeloma drug candidate SNS-01 at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference
  • Certain Senesco insiders entered into definitive stock purchase agreements to purchase all of the convertible debentures, warrants and common stock which are held by Stanford Venture Capital Holdings, Inc. and/or Stanford International Bank, Ltd.
  • Senesco entered into separate funding agreements, totaling $1.7 million, with Partlet Holdings Ltd., certain members of Senesco's Board of Directors and certain accredited investors, including Cato Holding Company, which is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization currently assisting Senesco with its SNS-01 development program; with the emphasis on initiating a Phase I clinical trial for multiple myeloma
  • Richard Dondero, Vice President of Research & Development at Senesco, delivered the Company's corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference

"SNS-01 continues to demonstrate potential as a possible treatment for multiple myeloma, most recently being the subject of a poster presentation at one of the most important oncology conferences of the year, the annual AACR-NCI-EORTC Conference," said Jack Van Hulst, President and Chief Executive Officer of Senesco.

The Company did not record any revenue for the three month period ended September 30, 2009. Total revenues of $200,000 for the three month period ended September 30, 2008 consisted of a milestone payment in connection with an agricultural license agreement.

Research and development expenses during the three month period ended September 30, 2009 were $575,291, compared with $504,386 during the three month period ended September 30, 2008, an increase of 14.1%. This increase was primarily a result of an $89,000 loss on the extinguishment of debt in connection with the issuance of common stock and warrants to Cato Holding Company in exchange for debt that was owed by Senesco to Cato Research Ltd. in the amount of $175,000, which was slightly offset by decrease in the cost of the research performed at the University of Waterloo as a result of the stronger U.S. dollar against the Canadian dollar.

General and administrative expenses were $494,955 for the three month period ended September 30, 2009, compared with $529,865 during the three month period ended September 30, 2008, a decrease of 6.6%. This decrease was due primarily to a $34,000 decrease in stock based compensation, and a $20,000 decrease in professional fees, which were a result of a decrease in legal and accounting fees related to the review of our securities filings. These decreases were slightly offset by a $15,000 increase in director fees associated with an increase in the size of the board of directors from eight to ten.

At September 30, 2009, Senesco had cash, cash equivalents and investments of $1,075,295, and working capital of $1,596,515, which the Company estimates will cover its expenses for approximately the next three months from September 30, 2009.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to successfully transition to new management; the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:                          Investor Relations Contact:
    Senesco Technologies, Inc.                FD
    Joel Brooks                               Brian Ritchie
    Chief Financial Officer                                212-850-5600
    (732) 296-8400
                         (A DEVELOPMENT STAGE COMPANY)

                                           September 30,        June 30,
                                                2009              2009
    ASSETS                                  (unaudited)

    Cash and cash equivalents                  $275,295          $380,569
    Short-term investments                      800,000         1,050,000
    Subscriptions receivable                    392,000                 -
    Prepaid expenses and other current
     assets                                   1,116,516         1,161,348
                                              ---------         ---------
     Total Current Assets                     2,583,811         2,591,917

    Property and equipment, net                   6,594             5,986
    Intangibles, net                          4,046,985         3,884,999
    Deferred financing costs                    488,046           632,324
    Security deposit                              7,187             7,187
                                              ---------         ---------
     TOTAL ASSETS                            $7,132,623        $7,122,413
                                             ==========        ==========

    Accounts payable                           $426,088          $976,680
    Accrued expenses                            561,208           355,937
                                              ---------         ---------
     Total Current Liabilities                  987,296         1,332,617

    Convertible note, net of discount            18,179             6,217
    Warrant liability                         1,311,975                 -
    Grant payable                                99,728            99,728
    Other liability                              14,028            16,017
                                              ---------         ---------
     TOTAL LIABILITIES                        2,431,206         1,454,579
                                              ---------         ---------

    Preferred stock, $0.01 par value;
     authorized 5,000,000 shares,
     no shares issued                                --                --
    Common stock, $0.01 par value;
     authorized 120,000,000 shares,
     issued and outstanding 24,777,638
     and 19,812,043, respectively               247,776           198,120
    Capital in excess of par, net of
     $88,000 subscription receivable         35,861,069        36,687,846
    Deficit accumulated during the
     development stage                      (31,407,428)      (31,218,132)
                                             ----------        ----------
     TOTAL STOCKHOLDERS' EQUITY               4,701,417         5,667,834
                                              ---------         ---------
      EQUITY                                 $7,132,623        $7,122,413
                                             ==========        ==========

    See Notes to Condensed Consolidated Financial Statements.
                                (A DEVELOPMENT STAGE COMPANY)

                                                                From Inception
                               For the Three    For the Three     on July 1,
                                Months Ended     Months Ended    1998 through
                                September 30,    September 30,   September 30,
                                     2009            2008            2009

    Revenue                             $--        $200,000       $1,450,000
                                  ---------       ---------       ----------
    Operating Expenses:
     General and administrative     494,955         529,865       24,426,148
     Research and development       575,291         504,386       12,886,850
                                  ---------       ---------       ----------
    Total Operating Expenses      1,070,246       1,034,251       37,312,998
                                  ---------       ---------       ----------
    Loss From Operations         (1,070,246)       (834,251)     (35,862,998)

    Sale of state income
     tax loss, net                       --              --          586,442
    Fair value - warrant
     Liability                    1,888,133              --        6,619,900
    Other noncash income                 --              --          321,259
    Interest income, net                347          23,057          523,660
    Amortization of debt
     discount and
     financing costs               (807,914)       (106,055)      (1,954,677)
    Interest expense on
     Convertible notes             (199,616)       (264,157)      (1,641,014)
                                  ---------       ---------       ----------
    Net Loss                      $(189,296)    $(1,181,406)    $(31,407,428)
                                  =========     ===========     ============
    Basic and Diluted Net
     Loss Per Common Share           $(0.01)         $(0.06)
                                  =========     ===========
    Basic and Diluted Weighted
     Average Number of Common
     Shares Outstanding          22,046,718      18,379,379
                                 ==========      ==========

SOURCE Senesco Technologies, Inc.

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
2. Senesco Announces H1N1 Influenza Survival Test Results in Mice
3. Senesco Chooses VGXI to Produce Factor 5A Plasmid
4. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
5. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
6. Senesco Technologies Initiates Preclinical Studies for Cancer Target
7. EF Johnson Technologies Announces Third Quarter Results
8. Ionian Technologies, Inc. Signs Molecular Diagnostic Manufacturing Agreement With Roche Diagnostics
9. Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
10. ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance
11. Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services
Post Your Comments:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):